We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.85B
AUM Growth
-$390M
Cap. Flow
-$60.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
29.91%
Holding
227
New
13
Increased
57
Reduced
57
Closed
7

Top Buys

Rank Stock Value
1
AMED
Amedisys
AMED
+$50.4M
2
FATE icon
Fate Therapeutics
FATE
+$49M
3
RVMD icon
Revolution Medicines
RVMD
+$46.7M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$43.8M
5
EPIX
ESSA Pharma
EPIX
+$40.9M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$301M
2
HALO icon
Halozyme
HALO
+$54.5M
3
CRL icon
Charles River Laboratories
CRL
+$47.7M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$34.2M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.84%
2 Industrials 0.82%
3 Technology 0.59%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVLR
176
DELISTED
Avalara, Inc.
AVLR
$402K ﹤0.01%
2,300
– –
ULTA icon
177
Ulta Beauty
ULTA
$20.4B
$397K ﹤0.01%
1,100
– –
TRMB icon
178
Trimble
TRMB
$12.3B
$395K ﹤0.01%
4,800
– –
SCI icon
179
Service Corp International
SCI
$11.4B
$392K ﹤0.01%
6,500
– –
OPT
180
DELISTED
Opthea Limited American Depositary Shares
OPT
$392K ﹤0.01%
49,000
-1,000
-2% -$7.59K
POOL icon
181
Pool Corp
POOL
$6.7B
$391K ﹤0.01%
900
– –
RVTY icon
182
Revvity
RVTY
$12.3B
$381K ﹤0.01%
2,200
– –
BKNG icon
183
Booking.com
BKNG
$138B
$380K ﹤0.01%
4,000
– –
ENTG icon
184
Entegris
ENTG
$19.7B
$378K ﹤0.01%
3,000
– –
MTCH icon
185
Match Group
MTCH
$8.84B
$373K ﹤0.01%
2,378
– –
MTD icon
186
Mettler-Toledo International
MTD
$26.8B
$372K ﹤0.01%
270
– –
NYT icon
187
New York Times
NYT
$11.6B
$370K ﹤0.01%
7,500
– –
TYL icon
188
Tyler Technologies
TYL
$12.2B
$367K ﹤0.01%
800
– –
KMX icon
189
CarMax
KMX
$8.27B
$365K ﹤0.01%
2,850
– –
WAB icon
190
Wabtec
WAB
$51.1B
$362K ﹤0.01%
4,200
– –
FAST icon
191
Fastenal
FAST
$54B
$361K ﹤0.01%
14,000
– –
MKL icon
192
Markel Group
MKL
$25B
$359K ﹤0.01%
300
– –
SBUX icon
193
Starbucks
SBUX
$118B
$357K ﹤0.01%
3,234
– –
VRSN icon
194
VeriSign
VRSN
$25.3B
$349K ﹤0.01%
1,700
– –
VRSK icon
195
Verisk Analytics
VRSK
$26.4B
$348K ﹤0.01%
1,739
– –
SWKS icon
196
Skyworks Solutions
SWKS
$9.06B
$346K ﹤0.01%
2,100
– –
ICE icon
197
Intercontinental Exchange
ICE
$82.4B
$344K ﹤0.01%
3,000
– –
WSO icon
198
Watsco Inc
WSO
$14.9B
$344K ﹤0.01%
1,300
– –
JMIA
199
Jumia Technologies
JMIA
$726M
$335K ﹤0.01%
18,000
– –
CLX icon
200
Clorox
CLX
$11.6B
$331K ﹤0.01%
2,000
– –
6 7
8
9 10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q3 2021 Portfolio in Review

As of Q3 2021, Bellevue Group held 227 positions worth $9.85B, down 3.8% from $10.2B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q3 2021 filing shows 13 new, 57 increased, 57 reduced and 7 closed positions. Its largest new stake was Sarepta Therapeutics: 569,168 shares worth $52.6M. The largest sale was Moderna, an estimated $301M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2021 buy was Sarepta Therapeutics: 569,168 shares worth $52.6M.
  • Bellevue Group added most to Amedisys in Q3 2021, an estimated $50.4M increase.
  • Bellevue Group's biggest Q3 2021 reduction was Moderna, cutting an estimated $301M.
  • Bellevue Group fully exited Eargo, Inc. Common Stock in Q3 2021, selling an estimated $17.3M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.85B portfolio in Q3 2021.
  • Bellevue Group opened 13 new positions and closed 7 in Q3 2021.
  • Bellevue Group's portfolio value fell 3.8% quarter-over-quarter to $9.85B.

Based on Bellevue Group's 13F filing for Q3 2021, filed 12 Nov 2021.